Genetic Cancer Risk: High-Penetrance Mutations, Polygenic Risk, and What Genetic Testing Actually Tells You

Genetic cancer risk is discussed as though it were a single, binary thing — a yes or no answerable by a test. In reality, it encompasses two biologically and clinically distinct phenomena that operate on completely different scales and require completely different clinical responses.

The first is rare high-penetrance germline mutations — variants in genes like BRCA1, BRCA2, and TP53 that are present in a fraction of a percent of the population but confer lifetime cancer risks of 50–90%+. These variants drive hereditary cancer syndromes, trigger intensive surveillance protocols, and carry implications for every first-degree relative.

The second is polygenic risk — the cumulative effect of hundreds or thousands of common genetic variants, each contributing a tiny increment to cancer risk, but together explaining much of the familial cancer clustering that isn’t explained by high-penetrance mutations. A person in the top 1% of polygenic risk scores for breast cancer faces approximately 3–4 times the population risk, without carrying any single identifiable “cancer gene.”

Understanding which category applies — and what specific tests can and cannot detect — is what transforms genetic information from abstract facts into clinically useful guidance.

Germline vs Somatic: Two Completely Different Things

One distinction must be clear before any discussion of genetic cancer risk can be meaningful: germline mutations and somatic mutations are fundamentally different things, generating different clinical questions and requiring different tests.

Germline mutations are present in every cell of the body — because they were inherited from a parent (or arose during embryonic development). A germline mutation can be detected from any tissue: blood, saliva, or a cheek swab. Because it is present in every cell, it can be transmitted to offspring with 50% probability. Germline mutations in cancer predisposition genes predict future cancer risk for the individual and signal risk for family members.

Somatic mutations are acquired in a specific cell during a person’s lifetime and are present only in that cell’s descendants — including any tumor that grows from it. Somatic mutations are detected from tumor tissue, not blood. They are not inherited, do not pass to children, and do not predict risk in family members. They are the targets of precision therapies: HER2 amplification guides trastuzumab use; EGFR mutations guide erlotinib; KRAS status predicts anti-EGFR therapy response.

Modern oncology uses both:

1. Germline panel testing (blood or saliva): identifies inherited cancer predisposition; guides prevention, surveillance, and risk-reducing interventions for the patient and their relatives
2. Somatic tumor profiling (tumor tissue or liquid biopsy): identifies actionable mutations driving a specific tumor; guides treatment selection; not relevant to family risk

One important overlap: when somatic tumor profiling reveals microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) in a colorectal or endometrial tumor, this triggers germline testing for Lynch syndrome — because the somatic tumor pattern may reflect an underlying inherited germline defect.

High-Penetrance Mutations: The Classic Hereditary Syndromes

“High-penetrance” means the mutation alone substantially drives cancer risk — typically conferring lifetime risk of 40–90%+ for specific cancer types. These mutations are rare in the population but have dramatic individual effects.

BRCA1 and BRCA2

Both encode proteins critical for homologous recombination DNA repair. When an inherited copy is inactivated and the second copy is lost through a somatic mutation in a specific cell, DNA repair failure leads to genomic instability and cancer.

• BRCA1: Lifetime breast cancer risk 50–72%; ovarian 44%; also associated with pancreatic cancer and specifically with triple-negative breast cancer
• BRCA2: Lifetime breast cancer risk 45–69%; ovarian 17%; substantial elevation in pancreatic, prostate (particularly aggressive disease), male breast, and melanoma risk

Prevalence: approximately 1 in 300–500 in the general population; approximately 1 in 40 in Ashkenazi Jewish individuals (three specific founder mutations).

TP53 — Li-Fraumeni Syndrome

Because p53 governs cell cycle arrest, DNA repair, and apoptosis across virtually all tissue types, germline TP53 inactivation confers risk broadly. Lifetime cancer risk exceeds 90%. Cancers include sarcomas, breast cancer (often before 30), brain tumors, adrenocortical carcinoma, and leukemia — frequently at young ages and with multiple primaries in one person.

APC — Familial Adenomatous Polyposis

Hundreds to thousands of colorectal adenomas develop in the second decade of life. Without prophylactic colectomy, colorectal cancer is essentially inevitable by age 40–50. Near-100% penetrance makes FAP one of the most deterministic genetic risks known.

MLH1, MSH2, MSH6, PMS2 — Lynch Syndrome

DNA mismatch repair gene mutations cause Lynch syndrome — the most common hereditary colorectal cancer syndrome, accounting for 3–5% of all CRC. Lifetime colorectal cancer risk ranges from 25–75% depending on the specific gene; endometrial cancer risk 25–60% in women. Lynch tumors show MSI-H on testing — now triggering routine Lynch germline testing in all newly diagnosed CRC and endometrial cancers.

CDKN2A, CDH1, PALB2

CDKN2A confers 60–90% lifetime melanoma risk and ~17% pancreatic cancer risk. CDH1 causes hereditary diffuse gastric cancer, with lifetime risk exceeding 70% — prophylactic total gastrectomy is frequently recommended because diffuse-type gastric cancer is undetectable at curable stages by endoscopy. PALB2 (NEJM 2014): lifetime breast cancer risk 35–58%, approaching BRCA2 level in multiply-affected families; also elevates pancreatic cancer risk.

Moderate-Penetrance Genes: The Expanding Panel

Modern multi-gene cancer panels test 25–80+ genes simultaneously. Beyond high-penetrance variants, they increasingly identify moderate-penetrance genes — more common in the population but conferring more modest risk elevations (typically 2–4× rather than 10–50×).

CHEK2

The most clinically common moderate-penetrance breast cancer gene. The CHEK2*1100delC variant is carried by approximately 1–2% of European-ancestry individuals. Heterozygous carriers have approximately 1.5–2× elevated breast cancer risk, along with modest elevations in colorectal, prostate, and thyroid cancer. Unlike BRCA1/2, CHEK2 alone rarely triggers the most intensive surveillance protocols — but combined with a strong family history or elevated polygenic risk score, the absolute risk can be clinically meaningful.

ATM

Heterozygous ATM variants (carried by ~0.5% of the general population) confer approximately 2× breast cancer risk and also elevate pancreatic cancer risk. ATM-deficient tumors may respond differently to certain DNA-damaging agents and PARP inhibitors — making ATM relevant both to risk prediction and treatment selection.

MUTYH (Autosomal Recessive)

MUTYH is unique: it requires two mutant copies to substantially elevate CRC risk (autosomal recessive inheritance). Biallelic carriers develop MUTYH-associated polyposis — a CRC risk approaching 50–80% lifetime, similar to attenuated FAP. Heterozygous carriers have only modestly elevated CRC risk (~1.5×). When a panel identifies one MUTYH variant, it is typically not immediately actionable; family testing to identify biallelic relatives is the key next step.

BRIP1, RAD51C, RAD51D

These homologous recombination genes confer approximately 3–5× elevated ovarian cancer risk. Clinical guidelines for these genes are still evolving — risk-reducing salpingo-oophorectomy may be recommended in some variants depending on personal and family history.

The clinical challenge with moderate-penetrance genes: management guidelines are less standardized than for BRCA1/2. Risk is real but the evidence base for specific surveillance intervals is thinner, and interpretation requires integrating the variant with family history and polygenic background.

Polygenic Risk Scores: The New Frontier

Most cancer genetic risk — including in families with multiple cancer cases but no identifiable high-penetrance mutation — reflects not a single gene but the aggregate effect of many common variants.

A polygenic risk score (PRS) sums hundreds to thousands of SNPs from genome-wide association studies, each associated with a small increment in cancer risk, into a single composite score. The score is continuous: some people land in the high-risk tail, others in the low-risk tail, most near the middle.

Breast Cancer PRS in Practice

In the largest validation study (Mavaddat et al., Am J Hum Genet 2019):

• Top 1% of PRS: approximately 3–4× population breast cancer risk
• Top 5%: approximately 2× population risk
• Bottom 1%: approximately 0.3× population risk

PRS Modifies Risk Even Within Mutation Carriers

The most clinically significant PRS finding: even within BRCA1 or BRCA2 mutation carriers, PRS substantially modifies absolute cancer risk.

• BRCA1 + high PRS: lifetime breast cancer risk approaches 80–90%
• BRCA1 + low PRS: lifetime risk may fall to 40–50%
• BRCA2 + high PRS: elevated absolute risk at younger ages
• BRCA2 + low PRS: meaningfully lower absolute risk with later onset

This has real implications for shared decisions about the age to start intensive surveillance, the threshold for risk-reducing surgery, and how aggressively to counsel individual carriers.

Current PRS Limitations

• Most PRS models were developed in European-ancestry populations. Clinical validity in East Asian, South Asian, African, and Latino populations is substantially reduced — a major equity concern in precision oncology.
• PRS does not detect high-penetrance mutations and cannot substitute for clinical panel testing in high-risk families.
• Clinical integration is evolving; many risk assessment tools are beginning to incorporate PRS alongside family history and standard clinical risk models.

Direct-to-Consumer Testing: What It Can and Cannot Tell You

Consumer genetic tests (23andMe, AncestryDNA) have made genetic testing widely accessible. For cancer risk, their limitations are significant and frequently misunderstood.

BRCA Testing: The Coverage Gap

DTC tests for BRCA variants check only the three most common Ashkenazi Jewish founder mutations: BRCA1 185delAG, BRCA1 5382insC, and BRCA2 6174delT.

• In Ashkenazi Jewish individuals: covers ~90% of BRCA mutations in that population — clinically meaningful
• In non-Ashkenazi individuals: covers only ~10% of all pathogenic BRCA variants — a negative result provides very limited reassurance

A non-Ashkenazi person with negative 23andMe BRCA results may carry any of hundreds of other pathogenic variants not tested. If personal or family history suggests hereditary breast/ovarian cancer, comprehensive clinical BRCA or multi-gene panel testing is required — regardless of DTC results.

PRS from DTC Tests

Consumer PRS estimates are based on earlier, smaller SNP sets and have not been validated in clinical decision-making settings. They may provide directional information but should not substitute for clinical risk assessment or alter screening decisions without professional evaluation.

When DTC Results Prompt Clinical Follow-Up

• Any positive finding for a recognized pathogenic variant → confirm with CLIA-certified lab + genetic counseling
• Personal or family history suggesting hereditary syndrome, even with negative DTC result → clinical panel testing warranted
• Unexpected high-risk PRS findings → discuss with a physician or genetic counselor before acting

Somatic Tumor Profiling: A Different Tool, Different Purpose

MSI-H and Immunotherapy

MSI-H/dMMR tumors respond dramatically to immune checkpoint inhibitors. Pembrolizumab is FDA-approved for all solid tumors that are MSI-H/dMMR regardless of origin (Le DT, NEJM 2015; KEYNOTE-158). MSI-H in CRC or endometrial tumors also triggers germline Lynch syndrome testing — roughly 15–20% of MSI-H colorectal tumors reflect underlying inherited Lynch syndrome.

TMB and Liquid Biopsy

Tumor mutational burden (TMB ≥10 mut/Mb) predicts immunotherapy response across tumor types. Liquid biopsy (cell-free DNA from blood plasma) enables somatic profiling without invasive tumor biopsy and is used for treatment monitoring and resistance detection — distinct from germline testing.

What Modifies Penetrance — Even With a Known Mutation

Polygenic background: PRS substantially modifies absolute breast cancer risk within BRCA1/2 carriers — up to 40 percentage points of difference between high and low PRS carriers.

Lifestyle factors: Obesity, tobacco, and alcohol amplify cancer risk even within mutation carriers, through mechanisms overlapping with the obesity-cancer and alcohol-cancer pathways described elsewhere.

OCP use in BRCA carriers: Reduces ovarian cancer risk approximately 50% (via ovulation suppression) but may modestly increase breast cancer risk — a balance requiring individualized counseling based on reproductive goals and timing.

Prophylactic surgery — the most effective modifier:

• RRSO (risk-reducing salpingo-oophorectomy): reduces ovarian cancer risk ~95% in BRCA1/2 carriers and reduces breast cancer-specific mortality ~50% in premenopausal BRCA1 carriers (through estrogen reduction)
• Risk-reducing mastectomy: reduces breast cancer risk approximately 90–95%

Frequently Asked Questions